This product is used for the treatment of respiratory distress syndrome in premature infants.
What is Survanta
500
Name 1 of the 10 Strategic Imperatives
What is
Meet/Exceed 2015 Earnings
Exceed Target for Global Humira Revenues in 2015
Achieve Late Stage Pipelines Approvals and Early-Mid Stage Pipeline Milestones
HCV Approval
Improve Humira Planned Market Erosion
Maximize Metabolic Franchise Sales and Deliver Above LRP
Improve Gross Margin Profile by 2 Points
Improve Projected 2014 EPS Growth through Royalties and Operational Effectiveness
Achieve Successful Transition off TSAs
Acquire or In-license Targeted Number of High Quality Assets